Market Blog

Agios Pharma & Eleven Biotherepeutics driven by sentiments

AGIO – Agios Pharmaceuticals, Inc is a biopharmaceutical company, engaged in the discovery and development of medicines for the treatment of cancer and genetic disorders.

AGIO – Agios Pharmaceuticals, Inc

Fundamentals Previously closed at 50.35
Day’s high 55.96
Day’s low 50.02
P/E ratio NA
EPS -3.62

 

Analysts opinion Agios Pharma announced positive results for its phase 1 Drug AG-348, used to treat anaemia. The stock was upgraded by Canaccord Genuity and J. P Morgan to “Buy”. Analyst confidence meter, a proprietary algorithm of Stockal gives 66% buy based on analyst ratings.
Sentiments AGIO fell, after having gained 8% Pre-Market today. The sentiment index is 100% negative according to Stockal proprietary algorithm.
Social Media Pulse The stock has 10% lower social media chatter than usual.

EBIO – Eleven Biotherepeutics is a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases

EBIO – Eleven Biotherepeutics, Inc

Fundamentals Previously closed at 1.87
Day’s high 1.98
Day’s low 1.62
P/E ratio NA
EPS -1.78

 

Analyst opinion EBIO announced a licensing deal with Hoffman La-Roche for development and commercialization of its treatment for eye disease. Under the agreement, EBIO will receive an upfront payment of $7.5 million and potential future payments of about $265 Million. Confidence Meter reads a 73% buy. This a proprietary algorithm of Stockal tracks Analyst confidence in the Stock.
Sentiments The sentiment index is 50% positive on Stockal proprietary algorithm.
Social Media Pulse The stock has 25% lower social chatter than usual.

Disclaimer: This blog contains an aggregated view of analysts and opinions by the author. Do not consider this as financial advice. See http://stockal.com/legalities/

Leave a Reply

Your email address will not be published. Required fields are marked *